Double-blind, placebo-controlled, multicenter, randomized, phase IIB neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer

Journal of Clinical Oncology

Volumn 32, Issue 10, 2014, Pages 1050-1057

  Guarneri, Valentina ^a   Generali, Daniele Giulio ^b   Frassoldati, Antonio ^c   Artioli, Fabrizio ^d   Boni, Corrado ^e   Cavanna, Luigi ^f   Tagliafico, Enrico ^g   Maiorana, Antonino ^h   Bottini, Alberto ^b   Cagossi, Katia ^d   Bisagni, Giancarlo ^e   Piacentini, Federico ^h   Ficarra, Guido ^h   Bettelli, Stefania ^h   Roncaglia, Enrica ^g   Nuzzo, Simona ^g   Swaby, Ramona ⁱ   Ellis, Catherine ⁱ   Holford, Clare ^j   Conte, PierFranco ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b CREMONA HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^d Ramazzini Hospital   (Italy)

^e S MARIA NUOVA HOSPITAL   (Italy)

^f Hospital of Piacenza   (Italy)

^g UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^h UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

ⁱ GLAXOSMITHKLINE   (United States)

^j GLAXOSMITHKLINE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LAPATINIB; LETROZOLE; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; ANTINEOPLASTIC AGENT; KI 67 ANTIGEN; NITRILE; PIK3CA PROTEIN, HUMAN; PROTEIN KINASE B; QUINAZOLINE DERIVATIVE; TRIAZOLE DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; DYSPEPSIA; ECHOGRAPHY; EXON; FATIGUE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MUCOSA INFLAMMATION; MUSCULOSKELETAL DISEASE; NAIL DISEASE; NAUSEA; PARTIAL MASTECTOMY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; WILD TYPE; ADJUVANT THERAPY; BREAST TUMOR; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; GENETICS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PHOSPHORYLATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; MUTATION; NEOADJUVANT THERAPY; NITRILES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; POSTMENOPAUSE; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 84901711830     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.4737     Document Type: Article

References (28)

1. Guarneri V, Broglio K, Kau SW, et al: Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24:1037-1044, 2006 (Pubitemid 46638799)
2. Rouzier R, Perou CM, Symmans WF, et al: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678-5685, 2005 (Pubitemid 41170290)
3. Fisher ER, Wang J, Bryant J, et al: Pathobiology of preoperative chemotherapy: Findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 95:681-695, 2002 (Pubitemid 34845919)
4. Eiermann W, Paepke S, Appfelstaedt J, et al: Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 12:1527-1532, 2001 (Pubitemid 34065880)
5. Smith IE, Dowsett M, Ebbs SR, et al: Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23:5108-5116, 2005 (Pubitemid 46224019)
6. Ellis MJ, Suman VJ, Hoog J, et al: Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: Clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol 29:2342-2349, 2011
7. Arpino G, Wiechmann L, Osborne CK, et al: Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29:217-233, 2008 (Pubitemid 351519691)
8. Polychronis A, Sinnett HD, Hadjiminas D, et al: Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogenreceptor positive and epidermal-growth-factor-receptorpositive primary breast cancer: A double-blind placebo-controlled phase II randomised trial. Lancet Oncol 6:383-391, 2005 (Pubitemid 40753744)
9. Smith IE, Walsh G, Skene A, et al: A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 25:3816-3822, 2007 (Pubitemid 47477255)
10. Cristofanilli M, Valero V, Mangalik A, et al: Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res 16:1904-1914, 2010
11. Osborne CK, Neven P, Dirix LY, et al: Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: A randomized phase II study. Clin Cancer Res 17:1147-1159, 2011
12. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006 (Pubitemid 46021510)
13. Johnston S, Pippen J Jr, Pivot X, et al: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538-5546, 2009
14. Bicciato S, Spinelli R, Zampieri M, et al: A computational procedure to identify significant overlap of differentially expressed and genomic imbalanced regions in cancer datasets. Nucleic Acids Res 37:5057-5070, 2009
15. Semiglazov VF, Semiglazov VV, Dashyan GA, et al: Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 110:244-254, 2007 (Pubitemid 47121883)
16. Alba E, Calvo L, Albanell J, et al: Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: Results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann Oncol 23:3069-3074, 2012
17. Dowsett M, Ebbs SR, Dixon JM, et al: Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: Influence of hormonal status and HER-2 in breast cancer-A study from the IMPACT trialists. J Clin Oncol 23:2477-2492, 2005 (Pubitemid 47050838)
18. Dowsett M, Smith IE, Ebbs SR, et al: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99:167-170, 2007
19. Pérez-Tenorio G, Stål O, Southeast Sweden Breast Cancer Group: Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 86:540-545, 2002 (Pubitemid 34185089)
20. Kirkegaard T, Witton CJ, McGlynn LM, et al: AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 207:139-146, 2005 (Pubitemid 41404144)
21. Tokunaga E, Kataoka A, Kimura Y, et al: The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. Eur J Cancer 42:629-635, 2006 (Pubitemid 43343685)
22. Guarneri V, Frassoldati A, Bottini A, et al: Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study. J Clin Oncol 30:1989-1995, 2012
23. Guarneri V, Frassoldati A, Ficarra G, et al: Trans-CHER-Lob: A biomarker analysis of the randomized phase II study of neoadjuvant chemotherapy plus trastuzumab, lapatinib or combined trastuzumab and lapatinib in HER2 positive operable breast cancer. Cancer Res 71:132s-133s, 2011 (suppl; abstr PD05-01)
24. O'Brien NA, Browne BC, Chow L, et al: Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 9:1489-1502, 2010
25. Esteva FJ, Guo H, Zhang S, et al: PTEN, PIK3CA, p-AKT, and p-p70S6K status: Association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 177:1647-1656, 2010
26. Dave B, Migliaccio I, Gutierrez MC, et al: Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 29:166-173, 2011
27. Miller TW, Balko JM, Arteaga CL: Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 29:4452-4461, 2011
28. Baselga J, Semiglazov V, van Dam P, et al: Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27:2630-2637, 2009